Research on the relationship between Legumain/Smad3 pathway and coronary atherosclerosis

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200058185

Enrollment

Unknown

Registered

2022-04-01

Start date

2022-03-18

Completion date

Unknown

Last updated

2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary atherosclerosis

Interventions

None listed

Eligibility

Sex/Gender

All

Age

35 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with coronary heart disease were hospitalized in the heart center of our hospital due to chest tightness and chest pain.

Exclusion criteria

Exclusion criteria: 1. Patients younger than 35 years or older than 80 years old; 2. Acute myocardial infarction; 3. New York heart function III-IV grade; 4. Previous balloon dilatation and stent implantation, coronary artery bypass grafting; 5. Chronic occlusion, severe calcification, tortuous lesions; 6. Liver and kidney dysfunction, blood system diseases, tumor history, thyroid gland dysfunction, severe diabetes, malnutrition, taking anti-anxiety, depression drugs, Immunosuppressant patients.

Design outcomes

Primary

Measure	Time frame
Legumain;SMAD3 Protein;	—

Countries

China

Contacts

Public ContactYunpeng Deng

Emergency General Hospital

dyp288@qq.com+86 18618343953

Outcome results